Of these mutations, 97.8% (1583/1616) were found in lung cancer, with 96.71% (1530/1583) of the mutations in lung cancer were located in EGFR, 1.1% (17/1583) located in ERBB2, 0.7% (12/1583) located in BRAF, and 1.4% (23/1583) in MAP2K1 (Table 1 and Figure 1a). This evidence concerns the gene MAP2K1 and lung carcinoma.